ADT May Protect Prostate Cancer Patients from COVID-19, Study Suggests

ADT May Protect Prostate Cancer Patients from COVID-19, Study Suggests
Androgen deprivation therapy (ADT), a form of hormone therapy commonly used to treat prostate cancer, appears to confer protection against the virus that causes COVID-19, lowering the rate of infections and their severity, a new study suggests. The study, "Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study," was published in the journal Annals of Oncology. COVID-19 is caused by the virus SARS-CoV-2. Recent research has shown this virus gets into cells by interacting with two proteins on the cells' surface: ACE2 and TMPRSS2. TMPRSS2 is expressed by cells throughout the body, including cells in the lungs and in the prostate. In both locations, this protein is regulated by the activity of androgens — so-called "male hormones," with
Subscribe or to access all post and page content.